指南与共识泌尿生殖技术与安全PETCT

18F-氟脱氧葡萄糖正电子发射断层显像/计算机断层显像分期改变浸润性膀胱癌的治疗推荐

Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer.
指南 / 共识 · Eur Urol Oncol · 2021-02-11

该回顾性分析纳入2011至2020年间在三级转诊中心连续接受分期增强CT(胸部及腹部)和FDG-PET/CT的711例浸润性尿路上皮膀胱癌患者,记录FDG-PET/CT前后的临床分期及基于分期的治疗推荐。FDG-PET/CT后184/711(26%)患者临床分期改变,127/711(18%)患者基于影像的治疗策略改变;65/711(9.1%)因检出远处转移由潜在治愈性治疗转为姑息治疗,50/711(7.0%)基于FDG-PET/CT选择新辅助/诱导化疗。FDG-PET/CT在15%患者中检出可疑第二原发肿瘤病灶,28/711(3.9%)确诊第二原发恶性肿瘤,10/711(1.4%)因此治疗改变;57/711(8.1%)出现假阳性次要发现。作者认为FDG-PET/CT提供重要增量分期信息,可能影响18%肌层浸润性膀胱癌患者的临床管理,但也会导致假阳性结果,并建议将FDG-PET/CT作为膀胱癌分期的一部分。

要点

  • FDG-PET/CT后26%(184/711)患者临床分期改变,18%(127/711)治疗推荐改变。
  • 9.1%(65/711)因FDG-PET/CT检出远处转移由潜在治愈性治疗转为姑息治疗。
  • 7.0%(50/711)基于FDG-PET/CT选择新辅助/诱导化疗。

关键影像表现/征象

  • FDG-PET/CT后184/711(26%)患者临床分期改变。
  • FDG-PET/CT检出可疑第二原发肿瘤病灶者占15%,其中28/711(3.9%)确诊第二原发恶性肿瘤。
  • 57/711(8.1%)患者出现假阳性次要发现。

临床应用与阅片要点

  • FDG-PET/CT后127/711(18%)患者基于影像的治疗推荐改变。
  • 65/711(9.1%)患者因FDG-PET/CT检出远处转移,由潜在治愈性治疗转为姑息治疗。
  • 50/711(7.0%)患者基于FDG-PET/CT被选择接受新辅助/诱导化疗。
  • 10/711(1.4%)患者因确诊第二原发恶性肿瘤而治疗改变。
  • 作者建议将FDG-PET/CT作为膀胱癌分期的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after standard conventional staging, in the largest cohort of MIBC patients to date. This is a retrospective analysis of 711 consecutive patients with invasive urothelial bladder cancer who underwent staging contrast-enhanced CT (chest and abdomen) and FDG-PET/CT in a tertiary referral center between 2011 and 2020. We recorded the clinical stage before and after FDG-PET/CT and treatment recommendation based on the stage before and after FDG-PET/CT. Clinical stage changed after FDG-PET/CT in 184/711 (26%) patients. Consequently, the recommended treatment strategy based on imaging changed in 127/711 (18%) patients. In 65/711 (9.1%) patients, potential curative treatment changed to palliative treatment because of the detection of distant metastases by FDG-PET/CT. Fifty (7.0%) patients were selected for neoadjuvant/induction chemotherapy based on FDG-PET/CT. Moreover, FDG-PET/CT detected lesions suspicious for second primary tumors in 15%; a second primary malignancy was confirmed in 28/711 (3.9%), leading to treatment change in ten (1.4%) patients. Contrarily 57/711 (8.1%) had false positive secondary findings. In conclusion, FDG-PET/CT provides important incremental staging information, which potentially influences clinical management in 18% of MIBC patients, but leads to false positive results as well. PATIENT SUMMARY: In this report, we investigated the impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scanning on treatment of bladder cancer patients. We found that FDG-PET/CT potentially influences the treatment of almost one-fifth of patients. We therefore suggest performing FDG-PET/CT as part of bladder cancer staging.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Voskuilen CS, van Gennep EJ, Einerhand SMH, et al. Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. Eur Urol Oncol. 2021. PMID: 33583752. doi:10.1016/j.euo.2021.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。